After the sermorelin result, these questions remain

Why is sermorelin banned in sport?

GHRH analogs are prohibited under WADA rules both in and out of competition. The analytical review of GHRH analog detection sits within that anti-doping context. Historical medical use and a short plasma half-life do not make the substance permitted in sport.

Does sermorelin show up on a drug test?

Specialized methods exist to detect GHRH analogs. In a small administration study of four men and eight women, IGF-I and the calculated GH-2000 score detected administration in all four men; menstrual-cycle variation complicated evaluation in women.

A separate dried-blood-spot method covered 46 doping agents, with proof-of-concept specimens for GHRP-2 and GHRP-6. It did not provide a sermorelin detection rate. I’m especially wary of treating a technically difficult assay as evidence of invisibility.

Is sermorelin safe?

Short studies reported mostly mild tolerability problems, including injection-site reactions. That is a bounded finding. The anti-aging editorial and the recent sports-medicine review leave long-term adult safety unresolved. The theoretical concern around sustained GH/IGF-1 elevation and cell growth remains a concern, rather than proof of cancer causation.

The effects notes give antibodies, glucose and other pituitary-hormone changes enough room to be understood separately. A single reassuring adjective would hide too much.

Does a higher IGF-1 result mean it worked?

It demonstrates a hormone response in the studied setting. The 14-day older-men study showed that response. It did not establish broad anti-aging benefit. ‘Worked’ needs an outcome attached: pediatric growth, hormone secretion and adult function are different questions.

For muscle and weight claims, the absence of matching outcome evidence is still the limiting issue. I’d be more impressed by a demonstrated functional gain than another comparison with a youthful hormone range.

What about sleep, brain fog or testosterone?

Sleep accounts are anecdotal and disagree. The cited nightly GHRH(1-29) study examined healthy elderly men and the GH/IGF-1 axis; it does not establish a general sleep treatment.

The cognitive trial used tesamorelin in older adults. It cannot establish that sermorelin clears brain fog. No study in the studies listed here shows a direct testosterone increase caused by sermorelin. Its GHRH-receptor mechanism concerns the GH axis.

Was it ever approved?

Yes. Sermorelin had a historical FDA-approved diagnostic and pediatric treatment role. Its US commercial withdrawal in 2008 was for business reasons, not a new finding of harm or lack of efficacy. The pediatric review and the review of the resulting diagnostic gap describe that past.

The present Category 1 compounding framework is a different regulatory status. Today’s compounded sermorelin has no FDA approval. The regulatory note puts those statements together.